RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
|Articles|October 15, 2013
Association of Clinical Trials Organizations (ACTO) Newsletter No. 7
Moscow 2013
Advertisement
The Association of Clinical Trials Organizations (ACTO) presented newsletter No. 7 with results from the first half of 2013 detailing the state of clinical trials in Russia.
During the first half of 2013, the Russian Ministry of Health issued 404 approvals for conducting clinical trials, down 10% from the same time last year. The number of international trials is also down 14.1% from last year, as is the number of bioequivalence studies, which is down 20.7%.
You can read the full report, including analysis of these numbers and thoughts on possible causes, (PDF)
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems and lack an audit trail, requiring sponsors to document oversight as a connected operating system with clear decision records, escalation pathways, and issue resolution from start to finish.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is expanding endpoint selection beyond the bounded experience of a single sponsor team—and surfacing options that traditional design thinking might never have considered.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
2
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
3
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
4
How AI Is Changing Endpoint Selection Before a Trial Even Starts
5